| 課程大綱 | Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs with an incidence of approximately 1 per 1000 annually in the United Status. About two thirds of patients with VTE present for care with DVT, and the remaining one third present with PE, which is the primary cause of mortality associated with VTE. With many of the known risk factors, including advanced age, cancer, immobility, surgery, obesity, trauma, pregnancy, oral contraceptives, hormone therapy, and thrombophilia, VTE is an important and growing public health problem. Recently, a marked increase has occurred in federal and national efforts to raise awareness and acknowledge the need for VTE prevention in high risk patients.Anticoagulation is the mainstay of therapy for patients with VTE. Initial anticoagulation refers to systemic anticoagulation administered for the first few days (typically up to 10 days) following a diagnosis of acute VTE. Long-term anticoagulant therapy is administered for a finite time beyond the initial period, usually 3 to 6 months, and occasionally up to 12 months. |
Prvention and management of Venous Thromboembolism